The tale of the long tail: The cytoplasmic domain of HIV-1 gp41

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 2-15

  Postler, Thomas S ^a,b,c   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ADAPTOR PROTEIN; ADAPTOR PROTEIN 1; ADAPTOR PROTEIN 2; ALPHA CATENIN; BETA CATENIN; CADHERIN; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS LYTIC PEPTIDE 1; LENTIVIRUS LYTIC PEPTIDE 2; PERILIPIN; PERILIPIN 3; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACTIN FILAMENT; AMINO ACID SEQUENCE; APOPTOSIS; BASIC LEUCINE ZIPPER MOTIF; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL MIGRATION; CYTOTOXICITY; ENDOCYTOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOREGULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SHORT SURVEY; VIRION; VIRUS GENOME; VIRUS LOAD; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ENDOCYTOSIS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ASSEMBLY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84871950126     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02053-12     Document Type: Short Survey

References (208)

1. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen A, Haseltine WA, Lee TH, Essex M. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-1094.
2. Veronese FD, Joseph B, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG. 1989. Identification of simian immunodeficiency virus SIVMAC env gene products. J. Virol. 63:1416 -1419.
3. Veronese FD, DeVico AL, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG. 1985. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229:1402-1405.
4. Blacklow SC, Lu M, Kim PS. 1995. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 34:14955-14962.
5. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
6. Gelderblom H, Özel M, Hausmann E, Winkel T, Pauli G, Koch MA. 1988. Fine structure of human immunodeficiency virus (HIV), immunolocalization of structural proteins and virus-cell relation. Micron Microsc. Acta 19:41- 60.
7. Grief C, Hockley DJ, Fromholc CE, Kitchin PA. 1989. The morphology of simian immunodeficiency virus as shown by negative staining electron microscopy. J. Gen. Virol. 70:2215-2219.
8. Lu M, Blacklow SC, Kim PS. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
9. Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, Zolla-Pazner S. 1989. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63:2674-2679.
10. Weiss CD, Levy JA, White JM. 1990. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J. Virol.64:5674 -5677.
11. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
12. Zhu P, Chertova E, Bess JJ, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U.S.A. 100:15812-15817.
13. + T cells by a complex of the 110K viral protein and the T4 molecule. Science 231:382-385.
14. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP,Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 384:184 -187.
15. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179 -183.
16. Bosch ML, Earl PL, Fargnoli K, Picciafuoco S, Giombini F, Wong-Staal F, Franchini G. 1989. Identification of the fusion peptide of primate immunodeficiency viruses. Science 244:694-697.
17. Freed EO, Myers DJ, Risser R. 1990. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. U.S.A. 87:4650-4654.
18. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J. 1987. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351-1355.
19. Haffar OK, Dowbenko DJ, Berman PW. 1988. Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. J. Cell Biol. 107:1677-1687.
20. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ. 1985. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 313:450-458.
21. Kitchen LW, Barin F, Sullivan JL, McLane MF, Brettler DB, LevinePH, Essex M. 1984. Aetiology of AIDS-antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature 312:367-369.
22. Montagnier L, Clavel F, Krust B, Chamaret S, Rey F, Barré-Sinoussi F, Chermann JC. 1985. Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 144:283-289.
23. Montefiori DC, Robinson WE, Mitchell WM. 1988. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 85:9248 -9252.
24. Stansell E, Desrosiers RC. 2010. Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J. Virol.84:8998 -9009.
25. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229 -1246.
26. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW. 1994. Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J. Virol. 68:463- 468.
27. Stansell E, Canis K, Haslam SM, Dell A, Desrosiers RC. 2011. Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J. Virol. 85:582-595.
28. Dewar RL, Vasudevachari MB, Natarajan V, Salzman NP. 1989. Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.J. Virol. 63:2452-2456.
29. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358 -361.
30. Hallenberger S, Moulard M, Sordel M, Klenk HD, Garten W. 1997. The role of eukaryotic subtilisin-like endoproteases for the activation ofhuman immunodeficiency virus glycoproteins in natural host cells. J. Virol. 71:1036 -1045.
31. Moulard M, Decroly E. 2000. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim. Biophys. Acta 1469:121-132.
32. Stein BS, Engleman EG. 1990. Intracellular processing of the gp160 HIV-1 envelope precursor: endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. J. Biol. Chem. 265:2640-2649.
33. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410:582-608.
34. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884 -1888.
35. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JLS, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 6:e1001249. doi:10.1371/journal.ppat.1001249.
36. Zhu P, Liu J, Bess JJ, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847- 852.
37. Krogh A, Larsson B, von Heijne G, Sonnhammer GEL. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol. 305:567-580.
38. Evans DT, Tillman KC, Desrosiers RC. 2002. Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. J. Virol. 76:327-337.
39. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228 -232.
40. Kirchhoff F, Kestler HW, Desrosiers RC. 1994. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J. Virol. 68:2031-2037.
41. Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, Broliden K. 1992. Identification of human neutralizationinducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 89:461- 465.
42. Cheingsong-Popov R, Callow D, Beddows S, Shaunak S, Wasi C, Kaleebu P, Gilks C, Petrascu IV, Garaev MM, Watts DM. 1992. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J. Infect. Dis.165:256 -261.
43. Goudsmit J, Meloen RH, Brasseur R. 1990. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 31:327-338.
44. Kennedy RC, Henkel RD, Pauletti D, Allan JS, Lee TH, Essex M, Dreesman GR. 1986. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 231:1556 -1559.
45. Postler TS, Martinez-Navio JM, Yuste E, Desrosiers RC. 2012. Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J. Virol. 86:1145-1157.
46. Vella C, Minor PD, Weller IV, Jenkins O, Evans D, Almond J. 1991. Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS 5:425- 430.
47. Eisenberg D, Wesson M. 1990. The most highly amphiphilic alphahelices include two amino acid segments in human immunodeficiency virus glycoprotein 41. Biopolymers 29:171-177.
48. Venable RM, Pastor RW, Brooks BR, Carson FW. 1989. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res. Hum. Retroviruses 5:7-22.
49. Kliger Y, Shai Y. 1997. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 36:5157-5169.
50. Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ. 2003. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J. Gen. Virol. 84:591- 602.
51. Dimmock NJ. 2005. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev. Med. Virol. 15:365-381.
52. Lu L, Zhu Y, Huang J, Chen X, Yang H, Jiang S, Chen YH. 2008.Surface exposure of the HIV-1 Env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 283:16723-16731.
53. Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC. 2010. Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One 5:e15261. doi:10.1371/journal.pone.0015261.
54. Liu S, Kondo N, Long Y, Xiao D, Iwamoto A, Matsuda Z. 2010.Membrane topology analysis of HIV-1 envelope glycoprotein gp41. Retrovirology 7:100. doi:10.1186/1742-4690-7-100.
55. Moreno MR, Pérez-Berná AJ, Guillén J, Villalaín J. 2008. Biophysical characterization and membrane interaction of the most membranotropic region of the HIV-1 gp41 endodomain. Biochim. Biophys. Acta 1778:1298 -1307.
56. Srinivas SK, Srinivas RV, Anantharamaiah GM, Segrest JP, Compans RW. 1992. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J. Biol. Chem. 267:7121-7127.
57. Haffar OK, Dowbenko DJ, Berman PW. 1991. The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes. Virology 180:439-441.
58. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, Sonigo P, Dokhelar MC, Benarous R. 1999. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J. Virol. 73:1350 -1361.
59. Bowers K, Pelchen-Matthews A, Hoening S, Vance PJ, Creary L, Haggarty BS, Romano J, Ballensiefen W, Hoxie JA, Marsh M. 2000. The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 1:661- 674.
60. Ohno H, Aguilar RC, Fournier Hennecke M-CS, Cosson P, Bonifacino JS. 1997. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 238:305-315.
61. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Hoening S, Benarous R, Thali M. 2001. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor.J. Virol. 75:2982-2992.
62. Boge M, Wyss S, Bonifacino JS, Thali M. 1998. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol.Chem. 273:15773-15778.
63. Byland R, Vance PJ, Hoxie JA, Marsh M. 2007. A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol. Biol. Cell 18:414-425.
64. LaBranche CC, Sauter MM, Haggarty BS, Vance PJ, Romano J, Hart TK, Bugelski PJ, Marsh M, Hoxie JA. 1995. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J. Virol. 69:5217-5227.
65. Rowell JF, Stanhope PE, Siliciano RF. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. J. Immunol. 155:473- 488.
66. Ishikawa H, Sasaki M, Noda S, Koga Y. 1998. Apoptosis induction by the binding of the carboxyl terminus of human immunodeficiency virus type 1 gp160 to calmodulin. J. Virol. 72:6574-6580.
67. Micoli KJ, Pan G, Wu Y, Williams JP, Cook WJ, McDonald JM. 2000.Requirement of calmodulin binding by HIV-1 gp160 for enhanced FASmediated apoptosis. J. Biol. Chem. 275:1233-1240.
68. Miller MA, Mietzner TA, Cloyd MW, Robey WG, Montelaro RC. 1993. Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res. Hum. Retroviruses 9:1057-1066.
69. Sham SWS, McDonald JM, Micoli KJ, Krishna NR. 2008. Solution structure of a calmodulin-binding domain in the carboxy-terminal region of HIV type 1 gp160. AIDS Res. Hum. Retroviruses 24:607- 616.
70. Srinivas SK, Srinivas RV, Anantharamaiah GM, Compans RW, Segrest JP. 1993. Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulinregulated proteins. J. Biol. Chem. 268:22895-22899.
71. Yuan T, Mietzner TA, Montelaro RC, Vogel HJ. 1995. Characterization of the calmodulin binding domain of SIV transmembrane glycoprotein by NMR and CD spectroscopy. Biochemistry 34:10690 -10696.
72. Kim EM, Lee KH, Kim JW. 1999. The cytoplasmic domain of HIV-1 gp41 interacts with the carboxy-terminal region of alpha-catenin. Mol.Cells 9:281-285.
73. Kim JT, Kim EM, Lee KH, Choi J-E, Jhun BH, Kim JW. 2002. Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin.Biochem. Biophys. Res. Commun. 291:1239 -1244.
74. Blot G, Lopez-Verges S, Treand C, Kubat NJ, Delcroix-Genete D, Emiliani S, Benarous R, Berlioz-Torrent C. 2006. Luman, a new partner of HIV-1 TMgp41, interferes with Tat-mediated transcription of the HIV-1 LTR. J. Mol. Biol. 364:1034 -1047.
75. Cosson P. 1996. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J. 15:5783-5788.
76. Manrique JM, Affranchino JL, Gonzalez SA. 2008. In vitro binding of simian immunodeficiency virus matrix protein to the cytoplasmic domain of the envelope glycoprotein. Virology 374:273-279.
77. Zhang H, Wang L, Kao S, Whitehead IP, Hart MJ, Liu B, Duus K,Burridge K, Der CJ, Su L. 1999. Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF.Curr. Biol. 9:1271-1274.
78. Blot G, Janvier K, Le Panse S, Benarous R, Berlioz-Torrent C. 2003. Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for Env incorporation into virions and infectivity. J. Virol. 77:6931- 6945.
79. Lopez-Vergès S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz- Torrent C. 2006. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc. Natl. Acad. Sci. U.S.A. 103:14947-14952.
80. Yang C, Spies CP, Compans RW. 1995. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc. Natl. Acad. Sci. U.S.A. 92:9871-9875.
81. Emerson V, Holtkotte D, Pfeiffer T, Wang Schnolzer I-HM, Kempf T,Bosch V. 2010. Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein. J. Virol. 84:1355-1365.
82. Postler TS, Desrosiers RC. 2012. The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe 11:181-193.
83. Viard M, Ablan SD, Zhou M, Veenstra TD, Freed EO, Raviv Y, Blumenthal R. 2008. Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry 47:1977-1983.
84. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS. 2005. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J. Virol. 79:106 -115.
85. Freed EO, Martin MA. 1996. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 70:341-351.
86. Mulligan MJ, Yamshchikov GV, Ritter GD, Gao F, Jin MJ, Nail CD, Spies CP, Hahn BH, Compans RW. 1992. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J. Virol.66:3971-3975.
87. Ritter GDJ, Mulligan MJ, Lydy SL, Compans RW. 1993. Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology 197:255-264.
88. Wilk T, Pfeiffer T, Bosch V. 1992. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 189:167-177.
89. Zingler K, Littman DR. 1993. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J. Virol.67:2824 -2831.
90. Kalia V, Sarkar S, Gupta P, Montelaro RC. 2003. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation. J. Virol. 77:3634 -3646.
91. Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA. 2005. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J. Virol. 79:12231-12241.
92. Jiang J, Aiken C. 2007. Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J. Virol. 81:9999 -10008.
93. Murakami T, Ablan S, Freed EO, Tanaka Y. 2004. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J. Virol. 78:1026 -1031.
94. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, Aiken C. 2004. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J. Virol. 78: 3429-3435.
95. Mammano F, Kondo E, Sodroski J, Bukovsky A, Göttlinger HG. 1995. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J. Virol. 69:3824-3830.
96. Murakami T, Freed EO. 2000. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl. Acad. Sci. U.S.A. 97:343-348.
97. Akari H, Fukumori T, Adachi A. 2000. Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J. Virol. 74:4891- 4893.
98. Dubay JW, Roberts SJ, Hahn BH, Hunter E. 1992. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J. Virol. 66:6616-6625.
99. Yu X, Yuan X, McLane MF, Lee TH, Essex M. 1993. Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J. Virol. 67:213-221.
100. Gabuzda DH, Lever A, Terwilliger E, Sodroski J. 1992. Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 66:3306-3315.
101. Jones DR, Suzuki K, Piller SC. 2002. A 100-amino acid truncation in the cytoplasmic tail of glycoprotein 41 in the reference HIV type 1 strain RF. AIDS Res. Hum. Retroviruses 18:513-517.
102. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, Doms RW, Hoxie JA. 1999. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J. Virol. 73:10310 -10319.
103. Shimizu H, Hasebe F, Tsuchie H, Morikawa S, Ushijima H, Kitamura T. 1992. Analysis of a human immunodeficiency virus type 1 isolate carrying a truncated transmembrane glycoprotein. Virology 189:534-546.
104. Shimizu H, Morikawa S, Yamaguchi K, Tsuchie H, Hachimori K, Ushijima H, Kitamura T. 1990. Shorter size of transmembrane glycoprotein of an HIV-1 isolate. AIDS 4:575-576.
105. Chakrabarti L, Emerman M, Tiollais P, Sonigo P. 1989. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J. Virol. 63:4395- 4403.
106. Hirsch VM, Edmondson P, Murphey-Corb M, Arbeille B, Johnson PR, Mullins JI. 1989. SIV adaptation to human cells. Nature 341:573-574.
107. Kodama T, Burns DP, Kestler HW, Daniel MD, Desrosiers RC. 1990.Molecular changes associated with replication of simian immunodeficiency virus in human cells. J. Med. Primatol. 19:431- 437.
108. Kodama T, Wooley DP, Naidu YM, Kestler HW, III, Daniel MD, Li Y, Desrosiers RC. 1989. Significance of premature stop codons in env of simian immunodeficiency virus. J. Virol. 63:4709-4714.
109. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC. 2005. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J. Virol. 79:12455-12463.
110. Yuste E, Reeves JD, Doms RW, Desrosiers RC. 2004. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J. Virol. 78:6775- 6785.
111. Shacklett BL, Weber CJ, Shaw KE, Keddie EM, Gardner MB, Sonigo P, Luciw PA. 2000. The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J. Virol. 74:5836 -5844.
112. Sauter MM, Pelchen-Matthews A, Bron R, Marsh M, LaBranche CC, Vance PJ, Romano J, Haggarty BS, Hart TK, Lee WM, Hoxie JA. 1996.An internalization signal in the simian immunodeficiency virus trans-membrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J. Cell Biol. 132:795- 811.
113. Bhakta SJ, Shang L, Prince JL, Claiborne DT, Hunter E. 2011. Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology 8:37. doi:10.1186/1742-4690-8-37.
114. Day JR, Muenk C, Guatelli JC. 2004. The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity. J. Virol. 78:1069 -1079.
115. West JT, Weldon SK, Wyss S, Lin X, Yu Q, Thali M, Hunter E. 2002. Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J. Virol. 76:3338 -3349.
116. Fultz PN, Vance PJ, Endres MJ, Tao B, Dvorin JD, Davis IC, Lifson JD, Montefiori DC, Marsh M, Malim MH, Hoxie JA. 2001. In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine- dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J. Virol. 75:278 -291.
117. Kuiken C, Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Wolinsky S, Korber B (ed). 2009. HIV sequence compendium 2009. Report LA-UR 09-03280. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
118. Traub LM. 2009. Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat. Rev. Mol. Cell Biol. 10:583-596
119. gag precursor protein. J. Virol. 70:6547- 6556.
120. Chertova E, Bess JWJ, Crise BJ, Sowder IR, Schaden TM, Hilburn JM,Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. 2002.Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325.
121. Dorfman T, Mammano F, Haseltine WA, Göttlinger HG. 1994. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 68:1689 -1696.
122. González SA, Affranchino JL, Gelderblom HR, Burny A. 1993. Assembly of the matrix protein of simian immunodeficiency virus into viruslike particles. Virology 194:548 -556.
123. Manrique JM, Celma CCP, Hunter E, Affranchino JL, González SA. 2003. Positive and negative modulation of virus infectivity and envelope glycoprotein incorporation into virions by amino acid substitutions at the N terminus of the simian immunodeficiency virus matrix protein. J. Virol. 77:10881-10888.
124. Yu X, Yuan X, Matsuda Z, Lee TH, Essex M. 1992. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J. Virol. 66:4966-4971.
125. Göttlinger HG, Sodroski JG, Haseltine WA. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A.86:5781-5785.
126. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI.1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. U.S.A. 93:3099 -3104.
127. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI. 1994. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J. Mol. Biol. 244:198 -223.
128. Veronese FD, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG. 1988. Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J. Virol. 62:795- 801.
129. Zhou W, Parent LJ, Wills JW, Resh MD. 1994. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68:2556 -2569.
130. Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ,Kingsman SM, Kingsman AJ. 1997. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J. Virol. 71: 3474-3483.
131. Fäcke M, Janetzko A, Shoeman RL, Kräusslich HG. 1993. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J. Virol. 67:4972- 4980.
132. Gallina A, Mantoan G, Rindi G, Milanesi G. 1994. Influence of MAinternal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 Gag protein. Biochem. Biophys. Res. Commun. 204:1031-1038.
133. Ono A, Orenstein JM, Freed EO. 2000. Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J. Virol.74:2855-2866.
134. Alcamí J, Laín de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB. 1995. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes.EMBO J. 14:1552-1560.
135. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K, Desrosiers RC. 2003. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J. Virol. 77:6823- 6835.
136. Chukkapalli V, Hogue IB, Boyko V, HuOno W-SA. 2008. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient Gag membrane binding. J. Virol. 82:2405-2417.
137. Ghanam RH, Samal AB, Fernandez TF, Saad JS. 2012. Role of the HIV-1 matrix protein in Gag intracellular trafficking and targeting to the plasma membrane for virus assembly. Front. Microbiol. 3:55. doi: 10.3389/fmicb.2012.00055.
138. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. 2004. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 101:14889 -14894.
139. Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF. 2006. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. U.S.A. 103:11364- 11369.
140. Murakami T, Freed EO. 2000. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J. Virol. 74:3548 -3554.
141. Freed EO, Martin MA. 1995. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J. Virol. 69:1984 -1989.
142. González SA, Burny A, Affranchino JL. 1996. Identification of domains in the simian immunodeficiency virus matrix protein essential for assembly and envelope glycoprotein incorporation. J. Virol. 70:6384-6389.
143. Alfadhli A, Barklis RL, Barklis E. 2009. HIV-1 matrix organizes as a hexamer of trimers on membranes containing phosphatidylinositol- (4,5)-bisphosphate. Virology 387:466-472.
144. Bauby H, Lopez-Verges S, Hoeffel G, Delcroix-Genete D, Janvier K, Mammano F, Hosmalin A, Berlioz-Torrent C. 2010. TIP47 is required for the production of infectious HIV-1 particles from primary macrophages. Traffic 11:455- 467.
145. Robinson MS. 2004. Adaptable adaptors for coated vesicles. Trends Cell Biol. 14:167-174.
146. Lodge R, Lalonde Lemay J-PG, Cohen EA. 1997. The membraneproximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells. EMBO J. 16:695-705.
147. Deschambeault J, Lalonde JP, Cervantes-Acosta G, Lodge R, Cohen EA, Lemay G. 1999. Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. J. Virol. 73:5010 -5017.
148. Chen BK. 2012. T cell virological synapses and HIV-1 pathogenesis. Immunol. Res. 54:133-139.
149. Díaz E, Pfeffer SR. 1998. TIP47: a cargo selection device for mannose 6-phosphate receptor trafficking. Cell 93:433- 443.
150. Bickel PE, Tansey JT, Welte MA. 2009. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim. Biophys. Acta 1791:419-440.
151. Carroll KS, Hanna J, Simon I, Krise J, Barbero P, Pfeffer SR. 2001. Role of Rab9 GTPase in facilitating receptor recruitment by TIP47. Science 292:1373-1376.
152. Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng J, Bellini WJ, Zhao L, Le Doux JM, Shaw MW, Luo CC, Lippincott-Schwartz J, Sanchez A, Rubin DH, Hodge TW. 2005. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J. Virol. 79:11742-11751.
153. Sivars U, Aivazian D, Pfeffer SR. 2003. Yip3 catalyses the dissociation of endosomal Rab-GDI complexes. Nature 425:856-859.
154. Blancou P, Evans DT, Desrosiers RC. 2005. PRA1 co-localizes with envelope but does not influence primate lentivirus production, infectivity or envelope incorporation. J. Gen. Virol. 86:1785-1790.
155. Bhattacharya J, Peters PJ, Clapham PR. 2004. Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles. J. Virol. 78:5500 -5506.
156. Rousso I, Mixon MB, Chen BK, Kim PS. 2000. Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 97:13523-13525.
157. Chan W-E, Lin H-H, Chen SS-L. 2005. Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals. J. Virol. 79:8374-8387.
158. Yang P, Ai L-S, Huang S-C, Li H-F, Chan W-E, Chang C-W, Ko C-Y, Chen SS-L. 2010. The cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein gp41 harbors lipid raft association determinants. J. Virol. 84:59 -75.
159. Oeckinghaus A, Ghosh S. 2009. The NF-κB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1:a000034. doi:10.1101/cshperspect.a000034.
160. Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. 1997. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J. Virol. 71:8657- 8665.
161. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
162. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML, Shaw GM, Allen S, Hahn BH, Gao F, UNAIDS and NIAID Networks for HIV Isolation and Characterization. 2001. Near fulllength clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res. Hum. Retroviruses 17:161- 168.
163. van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V, Salminen M, Berkhout B. 2004. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 78:3675-3683.
164. Regier DA, Desrosiers RC. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221-1231.
165. Bellas RE, Hopkins N, Li Y. 1993. The NF-κB binding site is necessary for efficient replication of simian immunodeficiency virus of macaques in primary macrophages but not in T cells in vitro. J. Virol. 67:2908- 2913.
166. Ilyinskii PO, Desrosiers RC. 1996. Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-κB and Sp1 binding elements. J. Virol. 70:3118 -3126.
167. Leonard J, Parrott C, Buckler-White AJ, Turner W, Ross EK, Martin MA, Rabson AB. 1989. The NF-κB binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J. Virol. 63:4919-4924.
168. Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA. 1991. Contribution of NF-κB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J. Virol. 65:4350-4358.
169. Osborn L, Kunkel S, Nabel GJ. 1989. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. U.S.A. 86: 2336-2340.
170. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. 1993. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J. 12:3551-3558.
171. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. U.S.A. 86:2365-2368.
172. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ. 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 339:70 -73.
173. Adhikari A, Xu M, Chen ZJ. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26:3214 -3226.
174. Wertz IE, Dixit VM. 2010. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harb. Perspect. Biol. 2:a0033500. doi:10.1101/ cshperspect.a003350.
175. Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME, Broder S, Gallo RC, Wong-Staal F. 1986. Infectious mutants of HTLV-III with changes in the 3= region and markedly reduced cytopathic effects. Science 233:655- 659.
176. Lee SJ, Hu W, Fisher AG, Looney DJ, Kao VF, Mitsuya H, Ratner L, Wong-Staal F. 1989. Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res. Hum. Retroviruses 5:441- 449.
177. Miller MA, Cloyd MW, Liebmann J, Rinaldo CRJ, Islam KR, Wang SZ, Mietzner TA, Montelaro RC. 1993. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 196:89 -100.
178. Miller MA, Garry RF, Jaynes JM, Montelaro RC. 1991. A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res. Hum. Retroviruses 7:511-519.
179. Costin JM. 2007. Cytopathic mechanisms of HIV-1. Virol. J. 4:100. doi: 10.1186/1743-422X-4-100.
180. Costin JM, Rausch JM, Garry RF, Wimley WC. 2007. Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein. Virol. J. 4:123. doi:10.1186/1743-422X-4-123.
181. Krebs J. 1998. The role of calcium in apoptosis. Biometals 11:375-382.
182. Cheung RK, Grinstein S, Gelfand EW. 1983. Permissive role of calcium in the inhibition of T cell mitogenesis by calmodulin antagonists. J. Immunol. 131:2291-2295.
183. Rao A, Luo C, Hogan PG. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-747.
184. Micoli KJ, Mamaeva O, Piller SC, Barker JL, Pan G, Hunter E, McDonald JM. 2006. Point mutations in the C-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication. Virology 344:468-479.
185. Pan Z, Radding W, Zhou T, Hunter E, Mountz J, McDonald JM. 1996. Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am. J. Pathol. 149:903-910.
186. + cells expressing gp160 of HIV. Virology 224:18 -24.
187. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler- Campbell JA, Hicks D, Sligh J. 1985. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J. Immunol. 135:3151-3162.
188. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1551-1560.
189. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
190. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, Gallo RC. 1986. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 231:850- 853.
191. Gilden J, Krummel MF. 2010. Control of cortical rigidity by the cytoskeleton: emerging roles for septins. Cytoskeleton (Hoboken) 67:477- 486.
192. Stolp BB, Fackler OTO. 2011. How HIV takes advantage of the cytoskeleton in entry and replication. Viruses 3:293-311.
193. Taylor MP, Koyuncu OO, Enquist LW. 2011. Subversion of the actin cytoskeleton during viral infection. Nat. Rev. Microbiol. 9:427- 439.
194. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. 2009. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 1796:91-98.
195. Montaner S, Perona R, Saniger L, Lacal JC. 1999. Activation of serum response factor by RhoA is mediated by the nuclear factor-κB and C/EBP transcription factors. J. Biol. Chem. 274:8506-8515.
196. Wang L, Zhang H, Solski PA, Hart MJ, Der CJ, Su L. 2000. Modulation of HIV-1 replication by a novel RhoA effector activity. J. Immunol. 164: 5369-5374.
197. Anastasiadis PZ. 2007. p120-ctn: a nexus for contextual signaling via Rho GTPases. Biochim. Biophys. Acta 1773:34-46.
198. Shapiro L, Weis WI. 2009. Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol. 1:a003053. doi:10.1101/ cshperspect.a003053.
199. Maiden SL, Hardin J. 2011. The secret life of α-catenin: moonlighting in morphogenesis. J. Cell Biol. 195:543-552.
200. Asada R, Kanemoto S, Kondo S, Saito A, Imaizumi K. 2011. The signalling from endoplasmic reticulum-resident bZIP transcription factors involved in diverse cellular physiology. J. Biochem. 149:507-518.
201. Mishra S, Ande SR, Nyomba BLG. 2010. The role of prohibitin in cell signaling. FEBS J. 277:3937-3946.
202. Osman C, Merkwirth C, Langer T. 2009. Prohibitins and the functional compartmentalization of mitochondrial membranes. J. Cell Sci. 122: 3823-3830.
203. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. 2011. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic Nef-deleted SIV. Cell Host Microbe 9:46-57.
204. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/ tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol. 18:388 -396.
205. Neil SJD, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425- 430.
206. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
207. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651- 662.
208. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM. 1999. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:194 -203